Siemens Healthineers Net Profit Falls on Higher Costs, Taxes
By Adria Calatayud
Siemens Healthineers reported a lower net profit for the fourth quarter of fiscal 2023 on higher charges and taxes, and forecast growth in sales and adjusted earnings for the year ahead.
Net profit for the quarter ended September amounted to 537 million euros ($574.6 million) compared with EUR630 million in the same period last year, the German healthcare company said Wednesday. On an adjusted basis, basic earnings per share fell 11% to EUR0.58.
The company attributed the fall to the impact of its discontinued rapid Covid-19 antigen test business on profitability, increased interest rates, higher severance charges and a higher tax rate.
Revenue inched higher at EUR6.06 billion from EUR6.00 billion, driven by growth in its Varian radiation-oncology business and its imaging segment, the company said. On a comparable basis, quarterly revenue grew 7.5%.
Analysts had expected Siemens Healthineers to post a quarterly adjusted EPS of EUR0.58 on revenue of EUR5.87 billion, according to consensus estimates provided by the company.
For the year ahead, Siemens Healthineers expects comparable revenue growth of between 4.5% and 6.5% and adjusted EPS of EUR2.10 to EUR2.30.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
November 08, 2023 01:20 ET (06:20 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks